Table 1.

UPN	Reason for SOT	Months of VALGAN prophylaxis	Antirejection treatmenta	Month of CMV disease
1 K	Retransplant/Graft Failure	0–3.5	3	NONE
2 L	Postnectrotic Type C Cirrhosis	0–3.5	Never	NONE
3 K	Alport’s Syndrome	0–3.5	Never	NONE
4 K	Diabetes Mellitus - Type II	0–3	Never	NONE
5 K	IgA Nephropathy	0–6	Never	NONE
6 K	IgA Nephropathy	0–3.5	Never	NONE
7 L	Postnectrotic Type C Cirrhosis	0–3	Never	NONE
8 L	Postnectrotic Type C Cirrhosis	0–3.5	Never	NONE
9 L	Postnectrotic Type C Cirrhosis	0–3	Never	NONE
10 L	Postnectrotic Type C Cirrhosis/Hepatocellular Carcinoma	0–3.5	2	7
11 L	Hepatocellular Carcinoma	0–3	Never	NONE
12 K	ESRD secondary to Hypertension	0–3.5	Never	4.5
13 K	Congenital Obstructive Uropathty	0–6	Never	NONE
14 L	Ulcerative Colitis	0–3	Never	NONE
15 K	Hypertensive Nephrosclerosis	0–6	Never	NONE
16 L	Postnectrotic Type C Cirrhosis	0–3	Never	NONE
19 K	ESRD secondary to hyperpara-thyroidism	0–3	Never	4.5
20 K	Lithium Toxicity	0–3.5	Never	NONE
21 L	Alcoholic Cirrhosis with Hepatitis C	0–3	2	4.5
22 K	Calcineurin Inhibitor Nephrotoxicity	0–6	Never	NONE
23 K	Chronic Glomerulo-nephritis	0–3	Never	4.5
24 L	Postnectrotic Type C Cirrhosis	0–3	Never	NONE
25 L	Postnectrotic Type B Cirrhosis	0–3	Never	NONE
26 K	Focal Glomerular Sclerosis	0–3.5	2	5
27 L	Postnectrotic Type C Cirrhosis	0–3	Never	NONE
28 K	Diabetes Mellitus - Type II	0–6	Never	NONE
29 K	Diabetes Mellitus -Type II	0–4	2	6.5
30 K	Diabetes Mellitus - Type II	0–3	4	3.5
31 K	Diabetes Mellitus - Type II	0–6	Never	NONE
32 L	Alcoholic Cirrhosis	0–3	Never	NONE
33 K	Chronic Glomerulonephritis	0–6	7, 8	NONE
34K	Chronic Glomerulo-nephritis	0–6	Never	8
35 K	Crescentic Glomerulonephritis	0–6	Never	NONE
36 K	Chronic Glomerulonephritis	0–6	Never	NONE
37 L	Postnecrotic Type C Cirrhosis	0–2	Never	6.5
38 K	Diabetes Mellitus - Type II	0–3.5	5	NONE
39 L	Postnectrotic Type C Cirrhosis	0–3	Never	NONE
3* L	Idiopathic/ Criptogenic Cirrhosis	0–3	3, 4.5, 6	4
8* L	Primary Biliary Cirrhosis	0–3	Never	5.5
15* L	Alcoholic Cirrhosis with Hepatitis C	0–3	Never	4

^aMonth of prednisone and antithymocyte globulin treatments for acute rejection.

Shaded rows indicate the 13 patients who developed CMV-dz;

^*identifies patient from Ref. [12] study;

K= kidney recipient; L= liver recipient